August 6, 2025 — Protagonist Therapeutics (Nasdaq:PTGX) today reported its financial results for the second quarter ended June 30, 2025, along with a corporate update. The company’s cash, cash equivalents, and marketable securities totaled $673.0 million as of June 30, 2025, which is anticipated to provide cash runway through at least the end of 2028.
A New Drug Application (NDA) for icotrokinra for treating adults and adolescents aged 12 and older with moderate to severe plaque psoriasis was submitted to the U.S. FDA in July. Phase 2b trial data of icotrokinra in ulcerative colitis is scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th.
Phase 3 VERIFY trial data for rusfertide in polycythemia vera was presented during a plenary session at ASCO, with the U.S. NDA filing on track for Q4.
“Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist,” said Dr. Dinesh V. Patel, the Company’s President and CEO.
Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact:
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
Source: Protagonist Therapeutics
